A phase lb/ll, open label, single arm study to assess efficacy and safety of alpelisib and capecitabine in patients with PIK3CA mutant metastatic colorectal cancer who failed two prior standard chemotherapies
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2513615
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Drug : Alpelisib: oral administration
In Phase lb, 200mg and 300mg once daily will be tested.
In Phase ll, the recommended phase ll dose (RP2D) in phase lb will be used.
Capecitabine: oral administration,
In Phase lb, 850mg, 1000mg, 1250mg twice daily will be tested.
In Phase ll, the recommended phase ll dose (RP2D) in phase lb twice daily on day 1 to 14 followed by 7 days off
Primary outcome(s): PFS, Progression Free Survival
创建时间：
2021-01-15
